RiboMed Receives $150,000 Epigenetics Research Contract to Continue Work Funded through IMAT to Develop Better Detection Technologies for Cancer

RiboMed Biotechnologies, Inc. recently announced the receipt of a $150,000 Phase I contract from the National Cancer Institute (NCI) to develop bisulfite-free, DNA methylation based diagnostic assays for prostate, bladder, kidney and testicular cancer. “This contract allows us to continue work that we started last year with NCI funding through its Innovative Molecular Analysis Technologies Program (IMAT),” said RiboMed CEO Michelle Hanna. Read the press release here.